January 31, 2025 - uniQure AMT-162 information brochure Submitted by wim@als.be on Fri, 01/31/2025 - 10:23
January 31, 2025 - uniQure Announces Recommendation Independent Data Monitoring Committee for its EPISOD1 Clinical Trial of AMT-162 for Treatment of SOD1-ALS Submitted by wim@als.be on Fri, 01/31/2025 - 10:21
January 09, 2025 - Topline Results AbbVie - Calico eIF2B Activator Fosigotifator Submitted by wim@als.be on Thu, 01/09/2025 - 14:12
January 07, 2025 - Topline Results Denali Therapeutics eIF2B Agonist DNL343 Submitted by wim@als.be on Tue, 01/07/2025 - 10:17
December 12, 2024 - Corcept Announces Results From Phase 2 DAZALS Study of Dazucorilant in ALS Submitted by wim@als.be on Thu, 12/12/2024 - 10:50
November 28, 2024 - Topline results PTC Therapeutics cardinALS trial Submitted by wim@als.be on Thu, 11/28/2024 - 09:00
October 15, 2024 - uniQure announces dosing first patient in Phase I-II clinical trial of AMT-162 for SOD1-ALS Submitted by wim@als.be on Tue, 10/15/2024 - 14:59
